Regulator’s BioLogics probe ends up inconclusiveKorea’s financial regulator wrapped up its review of a regulatory probe into whether Samsung BioLogics violated accounting rules, officials said Friday.
Details of the review were not disclosed due to a confidentiality agreement, but the review apparently failed to reach a consensus because there were some “majority and minority opinions” about the case, the Financial Services Commission said.
The review came after financial authorities gave a preliminary notice earlier last month to Samsung BioLogics that it broke accounting rules in 2015, a charge that the company has strongly denied.
The outcome of the review will be delivered to the Securities and Futures Commission, which will hold a meeting on Thursday to try to reach a final ruling.
More in Industry
Kia plant hit with infections for second time this month
LG Chem gets a boost in battery patent lawsuit against SK Innovation
[TEST DRIVE] There are few rides more comfortable than the Volvo S90
India is the battleground country for Samsung and Apple
Hyundai Motor unveils two electric models at Beijing car show